Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 225-625-8 | CAS number: 4979-32-2
Carcinogenicity
Administrative data
Description of key information
No reliable data are available.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
No classification is required according to the classification criteria of regulation no. 1272/2008 (GHS).
Additional information
There are no reliable data available. The carcinogenic potential of DCBS was investigated in an early subcutaneous long-term study with Wistar rats (Bayer AG 1975). Groups of 20 animals per sex were injected once a week over a period of 413 days with 1000 mg/kg bw test substance (total amount: 20000 mg/kg bw). An increased number of sarcomas located at the injection site were observed in all dose groups, but no signs of systemic toxicity were reported, and there was no difference in the survival between the control group and the dose group (Bayer AG 1975). However, the test design chosen was unusual, especially the route of administration, the subcutaneous application of the test substance, which is not in line with recommendations given in current carcinogenicity study guidelines and did not reflect a common exposure route in humans.
The metabolite 2-Mercaptobenzothiazole (MBT) is the relevant and common metabolite for all category members (CBS, TBBS, MDS and DCBS), data on 2-Mercaptobenzothiazole (MBT) CAS No. 149-30-4, EC no. 205-736-8 are also relevant for consideration of the carcinogenic potential of the category of substances. Refer to section 13.2 for the statement of carcinogenic potential of 2-Mercaptobenzothiazole (MBT) for more information.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
